Treatment with sildenafil, bosentan, or both in children and young people with idiopathic pulmonary arterial hypertension and Eisenmenger's syndrome;Tratamiento con sildenafilo y/o bosentán en niños y jóvenes con hipertensión arterial pulmonar idiopática y síndrome de Eisenmenger

Revista Espanola de Cardiologia

Volumn 60, Issue 4, 2007, Pages 366-372

  Raposo Sonnenfeld, Inés ^a   Otero González, Isabel ^a   Blanco Aparicio, Marina ^a   Ferrer Barba, Ángela ^a   Medrano López, Constancio ^a  

^a HOSPITAL JUAN CANALEJO   (Spain)

Author keywords

Bosentan; Eisenmenger's syndrome; Pulmonary arterial hypertension; Sildenafil

Indexed keywords

ACENOCOUMAROL; ALLOPURINOL; BOSENTAN; DIGOXIN; DIURETIC AGENT; SILDENAFIL;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; EISENMENGER COMPLEX; EXERCISE; FEMALE; FUNCTIONAL STATUS; HEART VENTRICLE SEPTUM DEFECT; HUMAN; INFANT; LONG TERM CARE; MALE; PULMONARY HYPERTENSION;

EID: 34250006520     PISSN: 03008932     EISSN: None     Source Type: Journal    
DOI: 10.1157/13101640     Document Type: Article

References (29)

1. Humbert M, Morrell NW, Archer SL, Stenmark KR, Mac Lean MR, Lang IM, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol. 2004;43:135-245.
2. D'Alonzo GE, Barst RJ, Ayres SM, Bagofsky EH, Brundage BH, Detre KM, et al. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med. 1991;115:343-9.
3. Houde C, Bohn DJ, Freedom R, Rabinovitch M. Profile of paediatric patients with pulmonary hypertension as judged by responsiveness to vasodilators. Br Heart J. 1993;70:461-8.
4. Galié N, Torbicki A, Barst R, Dartevelle P, Haworth S, Higenbottam T, et al. Guidelines on diagnosis and tratment of pulmonary arterial hypertension. The Task Force on diagnosis and treatment of pulmonary arterial hypertension of the European Society of Cardiology. Eur Heart J. 2004;25:2243-78.
5. Barst RJ, Dunbar I, Dingemanse J, Widlitz A, Schmitt K, Dovan A. Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension. Clin Pharmacol Ther. 2003;73:372-82.
6. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med. 1992;327:76-81.
7. Wilkins MR, Paul GA, Strange JW, Tunariu N, Gin-Sing W, Banya WA, et al. Sildenafil versus endothelin receptor antagonist for pulmonary hypertension (SERAPH) study. Am J Respir Crit Care Med. 2005;171:1292-7.
8. Barst RJ, Rubin LJ, Long WA, Mc Goon MD, Rich S, Badesch DB, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996;334:296-301.
9. Olschewski H, Simonneau G, Galié N, Higenbottam T, Naeije R, Rubin LJ, et al. Inhaled Iloprost for severe pulmonary hypertension. N Engl J Med. 2002;347:322-9.
10. Simonneau G, Barst RJ, Galié N, Naeije R, Rich S, Bourge RC, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension. Am J Respir Crit Care Med. 2002;165:800-4.
11. Rubin LJ, Badesh DB, Barst RJ, Galié N, Black CM, Keogh A, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002;346:896-903.
12. Galié N, Hinderleiter AL, Torbicki A, Fourme T, Simmoneau G, Pulido T, et al. Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and doppler measures in patients with pulmonary arterial hypertension. J Am Coll Cardiol. 2003; 41:1380-6.
13. Sitbon O, Badesh DB, Channick RN, Frost A, Robbins IM, Simonneau G, et al. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study. Chest. 2003;124:247-54.
14. Barst RJ, Ivy D, Dingemanse J, Widlitz A, Schmitt K, Doran A, et al. Pharmacokinetics, safety and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension. Clin Pharmacol Ther. 2003;73:372-82.
15. Abrams D, Schulze-Neick I, Magee AG. Sildenafil as a selective pulmonary vasodilator in childhood primary pulmonary hypertension. Heart. 2000;84:e4.
16. Schulze-Neick I, Hartenstein P, Li J, Stiller B, Nagdyman N, Hübler M, et al. Intravenous sildenafil is a potent pulmonary vasodilator in children with congenital heart disease. Circulation. 2003;108 Suppl II:167-73.
17. Michelakis ED, Tymchak W, Noga M, Webster L, Wu XC, Lien D, et al. Longterm treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation. 2003;109:2066-9.
18. Karatza AA, Bush A, Magee AC. Reversal of shunting in pulmonary hypertension after treatment with oral sildenafil. Cardiol Joung. 2002;12:561-2.
19. Jackson G, Chambers J. Sildenafil for primary pulmonary hypertension: short and long-term symptomatic benefit. Int J Clin Pract. 2002;56:397-8.
20. Mc Laughlin VV, Sitbon O, Badesh DB, Barst RJ, Black C, Galié N, et al. Survival with first line bosentan in patients with primary pulmonary hypertension. Eur Respir J. 2005;25:244-9.
21. Gatzoulis MA, Rogers P, Li W, Harries C, Cramer D, Ward S, et al. Safety and tolerability of bosentan in adults with Eisenmenger Physiology. Int J Cardiol. 2005;98:147-51.
22. Galié N, Beghetti M, Gatzoulis M, Granton J, Berger R, Lauer A, et al. (Breathe-5 investigators): Bosentan therapy in patients with Eisenmenger syndrome: a multicenter double-blind randomized placebo controlled study. Circulation. 2006;114:48-54.
23. Reffelman T, Klones RA. Therapeutic potential of phosphodiesterasa 5 inhibition for cardiovascular disease. Circulation. 2003;239:239-44.
24. Mikhail GW, Prarad SK, Li W, Rogers P, Chester AH, Bayne S. Clinical and haemodinamic effects of sildenafil in pulmonary hypertension: acute and mid-term effects. Eur Heart J. 2004;25:431-6.
25. Karatza AA, Bush A, Magee AG. Safety and efficacy of sildenafil therapy in children with pulmonary hypertension. Int J Cardiol. 2005;100:267-73.
26. Galié N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesh D, et al. Sildenafil citrate therapy for pulmonary arterial hipertensión. N Engl J Med. 2005;353:2148-57.
27. Hoeper MM, Faulenbach C, Golpon H, Winkler J, Welte T, Niedermeyer J. Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension. Eur Respir J. 2004; 24:1007-10.
28. Tei C, Dujardin KS, Hodge DO, Bailey KR, Mc Goon MD, Tajik AJ, et al. Doppler echocardiographic index for assessment of global fight ventricular function. J Am Soc Echocardiogr. 1996; 9:838-47.
29. Miyamoto S, Nagaya N, Satoh T, Kyotani S, Sakamaki F, Fujita M, et al. Clinical correlates and prognostic significance of six minute walk test in patients with primary pulmonary hypertension: comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med. 2000;161:487-92